

Office of Vermont Health Access Pharmacy Benefits Management Program DUR Board Meeting Agenda

February 12, 2008 6:30 – 9:00 p.m.

6:30 - 7:00

8:30 - 8:40

1. Executive Session

9. RetroDUR

	 Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2)) 	
2.	Introductions and Approval of DUR Board Minutes (Public Comment Prior to Board Action)	7:00 - 7:05
3.	OVHA Pharmacy Administration Updates	7:05 - 7:15
4.	Medical Director Update	7:15 - 7:20
5.	Follow-up Items from Previous Meeting Vytorin® & Zetia® – ENHANCE study and FDA Early Communication Data Review Erythropoiesis Stimulating Agents Communication to Prescribe	
6.	Clinical Update: Drug Reviews (Public comment prior to Board action) Alli® (orlistat OTC)	7:30 – 7:40
7.	Review of Newly-Developed/Revised Clinical Coverage Criteria (Public comment prior to Board action) Analgesics: Long Acting Narcotics (abbreviated review of Kade Anti-Infectives: Anti-Fungal: Allylamines Anti-Infectives: Anti-Fungal: Topical: Onychomycosis Anti-Infectives: Anti-Fungal: Azoles Anti-Infectives: Genital Antivirals Hepatitis C Agents (PA Length) Pulmonary: Antihistamines: 2nd Generation	
8.	 Drug Classes – New Contraceptives: Vaginal Ring Topical: Scabicides and Pediculicides Vitamins: Prenatal Multivitamins 	8:15 - 8:30

Cost Savings Analysis of Prior Initiatives Discussion of Planned/Ongoing evaluations

11. Updated New-to-Market Drug Monitoring Log	8:45 - 8:50
12. General Announcements	
FDA Safety Alerts	8:50 - 9:00
 Cough and Cold Preparations in Children less than 2 years old 	– safety concerns
 OrthoEvra Contraceptive Transdermal Patch – blood clots 	
 Antiepileptic Drugs - suicidal behavior or ideation 	
 Varenicline (Chantix[®]) - neuropsychiatric symptoms 	

8:40 - 8:45

13. Adjourn 9:00

10. New Drug Product Plan Exclusions